|
|
||||||||
CONCISE REVIEW |
Department of Tumor Immunology, University Hospital Nijmegen, The Netherlands
Key Words. Dendritic cell • Antigen-presenting cell • Primary immune response • T lymphocyte • Antitumor • MHC class I • MHC class II
Correspondence: Dr. Gill Marland, Department of Tumor Immunology, University Hospital Nijmegen, Philips van Leydenlaan 25, 6525 EX Nijmegen, The Netherlands.
The study of dendritic cells (DCs) has seen a rapid expansion in recent years, and their importance within the immune system is now widely recognized. Along with B lymphocytes and mononuclear phagocytes, DCs make up what are known as the professional antigen-presenting cells (APCs). These are cells which are capable of highly efficiently presenting antigens to the immune system in the context of both major histocompatibility complex class I and class II molecules. What makes DCs stand out from other professional APCs, however, is their seemingly unique ability to present antigen to T lymphocytes which have had no previous contact with antigen. This gives DCs a central role in the initiation of immune responses, and creates possibilities for their exploitation in the development of therapeutic strategies against tumors and other diseases.
What are the characteristics of DCs which enable them to carry out their specialized function? This is a question which is currently gaining much interest. While higher expression levels of the antigen-presentation machinery may account for this, there may also be as yet unidentified mechanisms at work. In this review, we will discuss the evidence for DC-mediated priming of both CD4+ and CD8+ naive T cells, both in vitro and in vivo, current ideas on how DCs achieve their potent function and the implications for the design and execution of immunotherapeutic strategies.
This article has been cited by other articles:
![]() |
S. He, Q. Cao, H. Yoneyama, H. Ge, Y. Zhang, and Y. Zhang MIP-3{alpha} and MIP-1{alpha} rapidly mobilize dendritic cell precursors into the peripheral blood J. Leukoc. Biol., December 1, 2008; 84(6): 1549 - 1556. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Morrow, B. Slobedman, A. L. Cunningham, and A. Abendroth Varicella-Zoster Virus Productively Infects Mature Dendritic Cells and Alters Their Immune Function J. Virol., April 15, 2003; 77(8): 4950 - 4959. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Abendroth, G. Morrow, A. L. Cunningham, and B. Slobedman Varicella-Zoster Virus Infection of Human Dendritic Cells and Transmission to T Cells: Implications for Virus Dissemination in the Host J. Virol., July 1, 2001; 75(13): 6183 - 6192. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Jenkins, L. L. Yasukawa, R. Bergen, C. Benike, E. G. Engleman, and A. M. Arvin Comparison of Primary Sensitization of Naive Human T Cells to Varicella-Zoster Virus Peptides by Dendritic Cells In Vitro with Responses Elicited In Vivo by Varicella Vaccination J. Immunol., January 1, 1999; 162(1): 560 - 567. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yanagihara, E. Komura, J. Nagafune, H. Watarai, and Y. Yamaguchi EBI1/CCR7 Is a New Member of Dendritic Cell Chemokine Receptor That Is Up-Regulated upon Maturation J. Immunol., September 15, 1998; 161(6): 3096 - 3102. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
